Kimberly-Clark Beats Q3 Estimates, Plans $48.7B Kenvue Acquisition
Kimberly-Clark reported Q3 adjusted EPS of $1.82, beating estimates by $0.07 on flat $4.15 billion revenue (beat by $50 million), with organic sales up 2.5% and a 36.8% gross margin reflecting 170 bps contraction. The company plans to acquire Kenvue in a $48.7 billion cash-and-stock deal and maintains its 53-year dividend increase streak.
1. Q3 Earnings Beat and Strategic Acquisition
Kimberly-Clark reported third-quarter adjusted EPS of $1.82 on October 30, 2025, surpassing consensus estimates by $0.07 and delivering revenue of $4.15 billion, $50 million above projections. Organic sales rose 2.5% year-over-year, driven by a 2.4% volume increase, despite a 2.2% headwind from the U.S. private-label diaper exit. Adjusted gross margin declined 170 basis points to 36.8% due to unfavourable pricing and tariff-related cost inflation, partially offset by productivity gains. The company disclosed plans to acquire Kenvue in a $48.7 billion cash-and-stock transaction, positioning Kimberly-Clark to expand its personal care portfolio and leverage scale efficiencies across global markets.
2. Dividend King Status and Yield Profile
Kimberly-Clark extended its dividend increase streak to 53 consecutive years, solidifying its membership among Dividend Kings. The company’s current payout equates to an annualized yield of approximately 5.1%, one of the highest in the consumer staples sector and roughly five times the S&P 500 average. Management’s conservative payout ratio and strong free cash flow generation support dividend sustainability, even under potential economic downturn scenarios.
3. Institutional Ownership Shifts and Analyst Ratings
In the latest quarter, Allspring Global trimmed its position by 49.1%, selling 21,259 shares and reducing its holding to 22,001 shares, while Vanguard Group increased its stake by 14.8% to over 40.4 million shares. Overall, institutional investors hold more than 76% of outstanding shares. Wall Street analysts maintain a consensus ‘Hold’ rating, with price targets ranging from $110 to $145. Recent revisions include a downgrade of the 2025 EPS outlook from $4.65 to $4.55 and mixed estimates for gross margin recovery amid cost-reduction initiatives.